Asian Pacific Journal of Tropical Medicine

REVIEW ARTICLE
Year
: 2022  |  Volume : 15  |  Issue : 7  |  Page : 293--307

Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review


Soumya Ranjan Satapathy1, Rudra Narayan Sahoo2 
1 School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
2 School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Odisha, India

Correspondence Address:
Rudra Narayan Sahoo
School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Odisha
India

Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities, parenteral administration, high cost, parasite resistance and stability. Hence, there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against VL. Developing formulation of new chemical entity for the treatment of VL is laborious, time consuming and associated with huge financial burden. However, screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for VL. Non-PEGylated liposome encapsulated doxorubicin (Myocet®) is proposed as an alternative treatment option for VL in this review article. Here, we covered the fundamental aspects of VL, loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL, as this liposomal delivery system of doxorubicin might passively target the intra- cellular regions of macrophage.


How to cite this article:
Satapathy SR, Sahoo RN. Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review.Asian Pac J Trop Med 2022;15:293-307


How to cite this URL:
Satapathy SR, Sahoo RN. Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review. Asian Pac J Trop Med [serial online] 2022 [cited 2022 Aug 12 ];15:293-307
Available from: https://www.apjtm.org/article.asp?issn=1995-7645;year=2022;volume=15;issue=7;spage=293;epage=307;aulast=Satapathy;type=0